文献速递帕金森病与运动障碍认知障碍与痴呆

特发性快速眼动期睡眠行为障碍中多巴胺转运体可用性的纵向变化

Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder.
PubMed 文献 · Neurology · 2020-09-28

本研究基于纵向前瞻性iRBD队列,纳入iRBD患者、帕金森病患者和健康对照,每2年进行嗅觉、神经心理评估和18F-FP-CIT PET扫描,通过主成分分析计算DAT模式。结果显示,基线嗅觉减退、便秘和轻度帕金森体征的iRBD患者DAT模式向PD模式分布,基线嗅觉减退是唯一与DAT模式纵向变化显著相关的生物标志物。基线PD模式DAT预测58%的转化者,联合嗅觉减退预测67%的转化,模拟神经保护试验所需样本量在特定亚组为每组63例。

要点

  • 基线DAT模式向PD模式分布的iRBD患者转化风险高。
  • 基线嗅觉减退是DAT模式纵向变化的唯一显著相关生物标志物。
  • 联合嗅觉减退和基线PD模式DAT可提高转化预测率,并减少临床试验样本量。

核心结论

  • 基线和纵向DAT模式监测有助于识别iRBD中高转化风险个体并筛选临床试验人群。

研究设计与样本

  • 纵向前瞻性iRBD队列研究,纳入iRBD患者、帕金森病患者和健康对照,每2年评估嗅觉、神经心理和运动症状,并进行18F-FP-CIT PET扫描,通过主成分分析计算DAT模式。

主要发现

  • 基线伴有嗅觉减退、便秘和轻度帕金森体征的iRBD患者DAT模式向PD模式分布,并与健康对照模式明显区分。
  • 部分iRBD患者随访期间DAT模式向PD模式移动,基线嗅觉减退是唯一显著相关的生物标志物。
  • 基线PD模式DAT预测58%的疾病转化者(风险比4.95,95%置信区间1.16-21.08)。
  • 基线PD模式DAT联合嗅觉减退预测67%的转化(风险比7.89,置信区间1.85-33.69)。

关键数值与推荐

  • 在基线DAT PD模式和嗅觉减退亚组中,以DAT模式年变化为结局的模拟神经保护临床试验所需样本量为每组63例。

临床怎么用

  • 对iRBD患者可结合基线DAT模式和嗅觉评估进行风险分层,高危患者可优先考虑纳入神经保护临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To elucidate longitudinal changes in the dopamine transporter (DAT) availability in association with the prodromal markers in idiopathic REM sleep behavior disorder (iRBD), we analyzed a longitudinal prospective iRBD cohort data. METHOD: The study cohort consisted of patients with iRBD, individuals with Parkinson disease (PD), and healthy controls. All participants were evaluated for olfaction, neuropsychological tests, and the Movement Disorders Society-Unified Parkinson's Disease Rating Scale and underwent 18F-FP-CIT PET scans every 2 years. We calculated the DAT pattern by performing the principal component analysis of tracer uptakes in 6 striatal regions. RESULT: DAT patterns in patients with iRBD with baseline hyposmia, constipation, and mild parkinsonian signs distributed toward the PD pattern and clearly distinguished from the healthy control pattern. The DAT pattern moved toward the PD pattern over time in some patients with iRBD during the follow-up, and baseline hyposmia was the only biomarker significantly associated with this change. Baseline PD pattern of DAT predicted 58% of disease converters (hazard ratio 4.95 [95% confidence interval 1.16-21.08]). The combination of hyposmia and baseline PD pattern of DAT predicted 67% of the conversion (hazard ratio 7.89 [confidence interval 1.85-33.69]). The estimated sample size required for a simulated neuroprotective clinical trial was 63 per group when the annual change of DAT pattern was used as an outcome in the subgroup with baseline DAT PD pattern and hyposmia, which is the smallest number reported so far. CONCLUSION: Baseline and longitudinal monitoring of the DAT pattern can be a useful biomarker in identifying individuals with a high risk of disease conversion and in selecting the potential population for clinical trials in iRBD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Shin JH, Lee JY, Kim YK, et al. Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. Neurology. 2020. PMID: 32989104. doi:10.1212/WNL.0000000000010942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。